Neurological disorders are among the most startling and debilitating conditions that you can suffer, with epilepsy being a particularly challenging one. Characterized by recurrent seizures, epilepsy ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
It's been a mediocre week for NeuroPace, Inc. ( NASDAQ:NPCE ) shareholders, with the stock dropping 13% to US$15.81 ...
NeuroPace projects 2025 revenue of $92-$96 million and aims for 20% revenue CAGR over three years. NeuroPace, Inc., a medical device company specializing in epilepsy treatment, announced its 2025 ...
-- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results